A missense point mutation (Ser515Phe) in the adrenoleukodystrophy gene in a family with adrenomyeloneuropathy: a clinical, biochemical, and genetic study

Matthias Vorgerd, Sigrid Fuchs, Martin Tegenthoff, Jean-Pierre Malin

Abstract

A 36 year old male patient with adrenomyeloneuropathy (AMN) developed progressive spastic paraparesis and sensory ataxia from the age of 18. Biochemical studies showed increased plasma concentrations of saturated very long chain fatty acids (VLCFAs), subclinical evidence of adrenal insufficiency, and primary hypogonadism. Three female family members had increased plasma concentrations of VLCFAs, suggesting carrier status of adrenoleukodystrophy (ALD). Molecular genetic analysis detected a missense point mutation (C1930T) in exon 6 within the ALD gene, which predicts substitution of an amino acid (Ser515Phe) that is conserved between the deduced amino acid sequence of the peroxisomal membrane protein PMP70 and ALD protein. Detection of this point mutation allows diagnosis of ALD or AMN, identification of heterozygotes, and prenatal diagnosis of ALD.

Keywords: adrenomyeloneuropathy; ALD gene; molecular genetic analysis

Adrenoleukodystrophy (ALD) is an X linked peroxisomal disease affecting 1/20,000 males either as cerebral ALD in childhood or as adrenomyeloneuropathy (AMN) in adulthood.1 Adrenomyeloneuropathy is a milder form of ALD with onset at 20–30 years of age and is clinically characterised by chronic progressive myelopathy with clinical manifestation of adrenal insufficiency.2 Heterozygotes of ALD or AMN may be clinically symptomatic.3

The accumulation of very long chain fatty acids (VLCFAs) in the nervous system and adrenal gland due to impaired β-oxidation in the peroxisomes is the principal biochemical abnormality of ALD.4 Clinical diagnosis of ALD or AMN is supported by finding increased VLCFAs in plasma.5

Recently, a candidate gene for ALD was identified by positional cloning that was found to be partially deleted in six of 85 unrelated patients.6

We describe a German family in which a male patient with AMN and three women were possible heterozygotes. Molecular genetic analysis of the ALD gene allows diagnosis of ALD or AMN, carrier detection, and prenatal diagnosis.

Case report

CLINICAL AND INVESTIGATIVE FEATURES

A 36 year old man developed slowly progressive weakness of his legs, ataxia, and alopecia at the age of 18 (III.1, fig 1).

On examination he had spastic paraparesis, incomplete sensory level below L1 on both sides, and gait ataxia. There were no clinical signs of Addison's disease. Magnetic resonance imaging of the head and cervical, thoracic, and thoracolumbar region was normal. Plasma cortisol concentration was slightly decreased, plasma ACTH was increased, and an ACTH stimulation test was negative. Plasma testosterone was decreased and LH and FSH were raised.

The patient's maternal 83 year old grandmother (I.1, fig 1) developed slowly progressive spastic paraparesis at the age of 60. She has had non-insulin dependent diabetes since the age of 70. Neurological examination showed no spastic paraparesis. Laboratory examination showed normal plasma concentrations of cortisol, ACTH, and a normal ACTH test.

The patient's 60 year old mother (II.2, fig 1) and his 25 year old sister (III.2, fig 1) had normal clinical examinations. Plasma cortisol and ACTH concentrations and an ACTH test were normal.

BIOCHEMICAL STUDIES

Plasma C22:0, C24:0, and C26:0 fatty acids were determined by liquid chromatography and compared with control samples.7

Plasma VLCFA concentrations (mean (SD)) in the patient with AMN and heterozygous family members

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>Patient with AMN</th>
<th>I</th>
<th>II</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>C22:0 (µg/ml)</td>
<td>14.9 (3.4)</td>
<td>17.1</td>
<td>12.8</td>
<td>17.8</td>
<td>17.3</td>
</tr>
<tr>
<td>C24:0 (µg/ml)</td>
<td>12.0 (2.5)</td>
<td>27.9</td>
<td>13.6</td>
<td>20.5</td>
<td>20.2</td>
</tr>
<tr>
<td>C26:0 (µg/ml)</td>
<td>0.21 (0.05)</td>
<td>1.12</td>
<td>0.61</td>
<td>0.62</td>
<td>0.49</td>
</tr>
<tr>
<td>C24:0/C22:0</td>
<td>0.81 (0.1)</td>
<td>1.75</td>
<td>1.07</td>
<td>1.15</td>
<td>1.16</td>
</tr>
<tr>
<td>C26:0/C22:0</td>
<td>0.013 (0.001)</td>
<td>0.066</td>
<td>0.048</td>
<td>0.035</td>
<td>0.028</td>
</tr>
</tbody>
</table>
In the patient plasma VLCFAs (C26:0) were increased fivefold and the plasma VLCFA ratio C26:0/C22:0 was also increased fivefold compared with values for controls. Plasma C26:0 VLCFAs and C26:0/C22:0 VLCFA ratios were increased twofold in the patient’s sister (III.2) and threefold in the mother (II.2) and maternal grandmother (I.1).

**MOLECULAR GENETIC ANALYSIS**

Genomic DNA of the patient with AMN presented in this study was analysed for possible sequence variations in the ALD gene by polymerase chain reaction (PCR) amplification and single strand conformation polymorphism (SSCP) analysis. The PCR segment containing exon 6 of the ALD gene showed a clearly aberrant SSCP pattern (data not shown). Direct sequencing of this particular segment showed a single nucleotide substitution (C1930T) in the patient’s sequence (fig 2), predicting the replacement of serine to phenylalanine at position 515 (Ser515Phe) in the deduced amino acid sequence of the ALD gene (numbering of nucleotides and amino acids to the ALD cDNA sequence as in Mosser et al1). This C1930T transition destroys a recognition site for the restriction endonuclease SacI in the ALD sequence and can therefore easily be detected by restriction enzyme analysis both in relatives of the patient and in unrelated controls (fig 1). SacI digestion of the wild type 298 base pair (bp) PCR product generates two fragments of 184 and 114 bp, whereas the PCR product carrying the C to T substitution is not cleaved. As shown in fig 1 the Ser515Phe mutation could also be detected in a heterozygous manner in the three female relatives of the patient—who also showed increased VLCFA concentrations—but not in the unaffected father. Restriction enzyme analysis of DNA samples from unaffected controls showed that this sequence mutation was not present in 60 unrelated X chromosomes (data not shown).

**Discussion**

Adrenoleukodystrophy is an X linked disease characterised by abnormal myelin accumulation of VLCFAs due to impaired β-oxidation in the peroxisomes. Different clinical phenotypes coexist within the same kindred.3,4 Childhood ALD is the more severe form with onset of neurological symptoms between 5 and 12 years of age. Demyelination in the CNS progresses rapidly and leads to death within a few years.5 The milder AMN form affects the spinal cord and peripheral nerves with onset at 20–30 years of age and a more progressive course.2,3

We presented a patient with clinical and biochemical evidence of AMN who developed progressive spastic paraparesis and sensory ataxia. Diagnosis was confirmed by greatly increased plasma VLCFAs.

Neuroradiological studies in patients with AMN show white matter alterations on brain MRI in nearly half of the patients and most patients show atrophy of the thoracic cord.3 Magnetic resonance imaging of the neuraxis was, however, normal in our patient.

According to Moser and Moser, most of the patients with ALD or AMN have clinical or biochemical evidence of impaired adrenal function or reserves.1 Adrenal function tests in our patient suggested adrenal insufficiency without clinical signs or symptoms of Addison’s disease. The patient’s primary hypogonadism could be due to damage of the testis in the course of the peroxisomal disease.6

Ten to fifteen per cent of women heterozygous for ALD or AMN develop progressive myelopathy and peripheral neuropathy, usually manifesting for the first time in their fifth
A missense point mutation (Ser515Phe) in the ALD gene in a family with AMN

A missense point mutation (Ser515Phe) in the ALD family likely impairs the proper function of the protein. Molecular genetic analysis of the genomic DNA of the patient with AMN presented in this study detected a missense point mutation (C1930T) in exon 6 of the ALD gene that predicts the change of serine to phenylalanine at position 515 (Ser515Phe) in the deduced amino acid sequence. Because Ser515 is present in one of the ATP binding folds that is entirely preserved between the ALD protein and PMP70, this substitution might disturb the proper binding of ATP and consequently impair the function of the protein.

If the Ser515Phe substitution found in the family was the only mutation present in the ALD gene, as our results suggest, it could be the likely cause of the disease. Additional examinations, such as in vitro expression studies, may provide a final proof. Nevertheless, as the nucleotide change does not seem to be a common polymorphism, and in the family cosegregates with the disease phenotype, it can be used for carrier and prenatal diagnostic tests in the patient's blood relatives.

Analysis of DNA of the patient's mother, maternal grandmother, and sister showed that they carry the ALD mutation Ser515Phe in a heterozygous manner. Therefore, the 25-year-old sister has a 50% chance of transmitting the mutated ALD gene to her offspring.

Identification of the Ser515Phe mutation principally allows prenatal diagnosis of ALD or AMN. It is not possible to predict the detailed clinical phenotype, however, because the same mutation can cause ALD or AMN within the same family. Additional factors presumably play a part in determining the final phenotype.